EGFR and non-small cell lung carcinoma: In a Phase Ib study of momelotinib in combination with erlotinib in EGFR-mutated, metastatic NSCLC, patients experienced neutropenia as an adverse effect of this drug combination, and the trial was halted (NCT02206763)[124].